Browse the evidence

Conservative management of obesity requires a structured, multidisciplinary lifestyle intervention (energy-reduced diet, increased physical activity, behavioral therapy) targeting a 5-10% weight loss within 6 months to improve comorbidities.

Start with a modest goal: lose 5-10% of your body weight over 6 months. This is achieved by eating 500-600 calories less per day and moving moderately for 150-300 minutes a week. Work with a team including a doctor and dietitian to make this sustainable.

Pharmacological weight loss therapy is indicated for BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidities, aiming for ≥ 5% weight loss within 3-4 months of reaching the target dose.

If lifestyle changes alone aren't enough and your BMI is high (≥30 or ≥27 with health issues), ask your doctor about approved weight-loss medications. These are used alongside lifestyle changes and aim for at least 5% weight loss within a few months of reaching the full dose.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (up to 25%) and improve cardiometabolic health, including cardiovascular and renal outcomes.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss and heart health. They work by mimicking hormones that control hunger and metabolism. Discuss these options with your doctor if lifestyle changes alone haven't worked.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (5-15%) and improve cardiometabolic risk factors in adults with obesity, with efficacy increasing with higher doses.

If lifestyle changes alone haven't led to significant weight loss, GLP-1 or dual agonist medications can help you lose 5-15% of your body weight and improve your blood sugar and heart health. These are prescription medications that work by mimicking hormones that control hunger. You will need to start with a low dose and slowly increase it to avoid stomach side effects like nausea.

Phentermine/topiramate combination therapy produces significant weight loss (up to 8.6% vs placebo) and improves metabolic markers, but is contraindicated in patients with unstable cardiovascular disease.

This combination medication can help you lose weight and improve your metabolic health. It works by suppressing appetite and increasing energy expenditure. Because it can affect heart rate and blood pressure, it is not suitable for everyone, especially those with heart conditions. You must start with a low dose and increase it slowly to minimize side effects like tingling or dry mouth.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significantly greater weight loss than older anti-obesity medications (orlistat, phentermine/topiramate, naltrexone/bupropion) by targeting hypothalamic appetite regulation and delaying gastric emptying.

If lifestyle changes alone haven't worked, newer GLP-1 medications (like semaglutide or tirzepatide) are significantly more effective than older drugs, achieving 15-20% weight loss compared to 3-5% with older options. However, they are expensive, require weekly injections (mostly), and can cause gastrointestinal side effects. They are best considered for those with obesity-related comorbidities who have failed lifestyle interventions.

GLP-1 receptor agonists (semaglutide 2.4mg) and dual agonists (tirzepatide 15mg) produce significant, sustained weight loss (11.8% and 14.7-20.9% respectively) compared to placebo, but discontinuation leads to significant weight recurrence (approx. 2/3 of lost weight).

If you qualify (BMI ≥27 with comorbidity or ≥30), GLP-1 agonists like semaglutide (2.4mg weekly) or tirzepatide (15mg weekly) are highly effective, producing 12-21% weight loss. However, these are chronic treatments; stopping them leads to regaining ~2/3 of the weight. Discuss coverage and long-term commitment with your provider.

Type 2 diabetes remission is achievable through significant weight loss (specifically targeting ectopic fat in the liver and pancreas) via very low-calorie diets or bariatric surgery, challenging the view that T2D is an irreversible progressive disease.

To put Type 2 Diabetes into remission, you must lose a significant amount of weight (typically >15kg or >15% of body weight) to remove fat from your liver and pancreas. This is best achieved through a medically supervised Very Low-Calorie Diet (500-800 kcal/day) using meal replacements for 3 months, followed by a structured maintenance plan. This approach is most effective if you have had diabetes for less than 6-10 years.

GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide) and dual/triple agonists induce T2D remission primarily through significant weight loss and reduction of ectopic fat, with some direct beta-cell protective effects.

If you have prediabetes or early Type 2 Diabetes and struggle with weight, GLP-1 or GLP-1/GIP agonists (like Semaglutide or Tirzepatide) are highly effective at restoring normal blood sugar levels. These drugs work by reducing appetite and body weight, with some also having direct benefits on beta-cells. They are often used alongside lifestyle changes.

Semaglutide significantly reduces all-cause mortality and myocardial infarction risk in patients at increased risk of cardiovascular events, with high-certainty evidence.

If you are at high risk for heart issues, semaglutide is a proven treatment that lowers your risk of dying or having a heart attack. While you may experience stomach upset, these side effects are generally not serious and are outweighed by the life-saving benefits. Consult your doctor to see if this medication is appropriate for your specific risk profile.

Once-weekly subcutaneous semaglutide 2.4 mg, when combined with lifestyle interventions, produces clinically significant weight loss (average 14.9-16.0% body weight reduction) in adults with obesity or overweight with comorbidities, significantly outperforming placebo and daily liraglutide 3.0 mg.

If you have obesity or are overweight with a related health issue, once-weekly semaglutide 2.4 mg is a highly effective tool for weight loss when combined with diet and exercise. It works by mimicking a hormone that slows digestion and reduces appetite. You start with a low dose to minimize stomach upset, then increase it weekly until you reach the full dose. Expect significant weight loss (around 15%) over 6-8 months, which is much more than diet and exercise alone. Be aware of potential side effects like nausea, which usually fade, and avoid the medication if you have a specific family history of thyroid cancer.

Tirzepatide (5-15 mg) produces significantly greater weight loss, waist circumference reduction, and HbA1c improvement compared to placebo, insulin, and GLP-1 receptor agonists in adults with type 2 diabetes or obesity.

Tirzepatide is a highly effective treatment for weight loss and blood sugar control, outperforming existing GLP-1 drugs and insulin. It requires weekly injections and careful dose titration to manage gastrointestinal side effects like nausea.

Combining moderate-to-vigorous aerobic exercise with 3.0 mg/day liraglutide yields superior weight loss maintenance and metabolic health improvements compared to either intervention alone or placebo.

To maintain weight loss effectively, combine daily 3.0 mg liraglutide with a structured exercise routine aiming for 150 minutes of moderate or 75 minutes of vigorous activity per week. This combination is significantly more effective for weight loss and metabolic health than using either method alone.

For patients with Class I obesity (BMI 30–34.9 kg/m2), newer obesity management medications (OMM) such as tirzepatide and semaglutide provide total body weight loss (TBWL) efficacy equivalent to major metabolic bariatric surgeries (MBS) like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB), while offering superior safety and tolerability profiles.

If you have Class I obesity (BMI 30-34.9), you no longer need to choose between surgery and medication as your first step. Newer medications like tirzepatide and semaglutide can help you lose as much weight as major surgeries like gastric bypass, but with fewer risks and side effects. This makes medication a highly effective and safer first-line treatment for this specific group.

Individualized Medical Nutrition Therapy (MNT) provided by a Registered Dietitian Nutritionist (RDN) significantly improves glycemic control (A1C reduction up to 2.0% in T2D and 1.9% in T1D) and is cost-effective, making it a fundamental component of diabetes management.

Ask your doctor for a referral to a Registered Dietitian Nutritionist (RDN) who specializes in diabetes. Expect about 3-6 visits in the first six months to build your personalized plan, followed by at least one check-in per year. This is covered by Medicare and many insurers. The goal is to lower your A1C and manage weight through sustainable changes tailored to your culture and preferences, not a rigid diet.

Intensive lifestyle interventions modeled on the Diabetes Prevention Program (DPP), including individualized MNT and physical activity, reduce the incidence of type 2 diabetes by 58% in adults with prediabetes and overweight/obesity.

If you have prediabetes and are overweight, ask your doctor about a DPP-modeled lifestyle program. The goal is to lose 7-10% of your body weight and get 150 minutes of moderate exercise per week. This approach is proven to cut your risk of developing type 2 diabetes by more than half. It is often covered by insurance.

Consuming 30-60 g of carbohydrate per hour during endurance exercise lasting >70 minutes improves performance and maintains blood glucose.

For workouts longer than 70 minutes, drink a sports drink containing 6-8% carbohydrates. Aim for 30-60 grams of carbs per hour, sipping small amounts every 10-15 minutes.

Sarcopenia is a potentially reversible disease defined by the concurrent combination of reduced muscle mass and muscle strength, with muscle-specific strength also included as a component.

Sarcopenia is not just 'getting old'; it is a reversible condition defined by low muscle mass and strength. To address it, focus on resistance training and adequate protein intake to build muscle and strength, as these are the core components of the disease definition.

Eliminating sugar-sweetened beverages reduces body weight in adolescents and children.

If you are an adolescent or child, or if you are helping one, stop drinking sugary beverages. This simple change has been shown in large trials to reduce body weight over 1-1.5 years.

Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly (5-15 mg), significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity, outperforming placebo, GLP-1 receptor agonists (semaglutide, dulaglutide), and basal insulins.

Tirzepatide is a once-weekly injection approved for type 2 diabetes and obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to lower blood sugar and reduce appetite. Clinical trials show it leads to significant weight loss (up to 22% in obesity) and better blood sugar control than many existing medications, including standard GLP-1 drugs and insulin. Treatment starts at a low dose to manage side effects like nausea, which usually decrease over time.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significantly greater reductions in HbA1c and body weight compared to semaglutide 1 mg and basal insulins in adults with type 2 diabetes.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with type 2 diabetes, outperforming other common treatments like semaglutide and basal insulins in clinical trials.

GLP-1 receptor agonists and related incretin-based therapies are effective pharmacological interventions for obesity and type 2 diabetes, offering superior weight loss and cardiovascular benefits compared to previous treatments.

GLP-1 receptor agonists are a major advance in obesity treatment, offering significant weight loss and cardiovascular benefits. They work by mimicking gut hormones that regulate appetite and blood sugar. Consult a doctor to see if they are appropriate for you.

Sustained weight loss requires a permanent reduction in energy intake below the body's reduced energy expenditure, as metabolic adaptation lowers energy needs during weight loss.

To keep weight off, you must eat less than you did before you lost the weight, because your body burns fewer calories at a lower weight. This isn't a failure of willpower; it's biology. You need to permanently adjust your intake to match your new, lower energy needs.

Once-weekly subcutaneous semaglutide 2.4 mg significantly reduces systemic inflammation, measured by C-reactive protein (CRP), in adults with overweight or obesity compared to placebo.

If you have overweight or obesity, taking once-weekly semaglutide 2.4 mg significantly lowers your C-reactive protein (CRP), a key marker of systemic inflammation and cardiovascular risk. This benefit occurs alongside weight loss and is consistent regardless of your baseline BMI or diabetes status. The treatment involves a gradual dose escalation over 16 weeks to minimize side effects, followed by maintenance at 2.4 mg weekly for 68 weeks, combined with lifestyle changes.